International Trials Day - Tally
Biogen Tally Trial
Full study name: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study To Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
GMMH is offering the opportunity for service users to take part in a clinical trial investigating the use of a new treatment for Cognitive Impairment Associated with Schizphrenia (CIAS). Almost all people living with schizophrenia have CIAS. CIAS refers to some issues that people with schizophrenia may have, including having trouble remembering things, learning new things, or making good decisions. While therapies exist to address some symptoms of schizophrenia, there are currently no approved medicines for the cognitive impairment associated with this condition.
The TALLY clinical trial aims to see if a new investigational medication could potentially impact this unmet need and aims to understand if an investigational medication could be safe and potentially effective in impacting attention and memory in people with schizophrenia. Service users under GMMH who meet the below criteria may be eligible to take part:
- - Are aged 18-55
- -Have been diagnosed with schizophrenia for at least two years
- -Are taking a consistent dose of no more than two antipsychotic medicines
- -Have not been hospitalised due to schizophrenia for at least 12 weeks
- -Have a dedicated study partner
- – someone who interacts with them (in person or by telephone) at least two times per week and can accompany them to certain visits
For more information on the trial, please contact: Leanne.howieson@gmmh.nhs.uk
